Premier Biomedical Integrates CBD-Based Pain Relief Products Business; Expands Current and New Product Offerings
July 13 2017 - 10:00AM
InvestorsHub NewsWire
El Paso,
Texas - July 13, 2017 -
InvestorsHub NewsWire - Premier
Biomedical, Inc. (OTCQB:
"BIEI") announced today they have terminated the joint venture,
Premier Biomedical Pain Management Solutions LLC, which was
formed in September of 2016. Premier Biomedical has
integrated the pain relief products business into a division of
Premier, which will continue to develop and market an expanded
array of natural and synthetic, 50-state legal CBD-based,
generalized, neuropathic, and localized pain relief treatment
products. Their products will continue to be sold through
their website, www.painreliefmeds.com ,as well as through an expanding
network of distributors, pharmacies, healthcare professionals, and
pain clinics.
Premier Biomedical
earlier this week announced the introduction of topical skin
patches with higher CBD content than previously. They also
announced a higher CBD content topical roll-on to be introduced
later this quarter.
William A. Hartman,
President and CEO of Premier Biomedical, Inc. stated, “This
restructuring allows us to access a wider array of resources to
further our aggressive new product plans to better position us as a
leader in the CBD-based pain relief products industry. The
global pain relief market is currently in excess of $100 billion
annually. We believe that our current and future products
represent an effective alternative to opioid-based pain relief
drugs without the associated health risks and addiction potential
of narcotics.”
About Premier Biomedical,
Inc.
Premier Biomedical, Inc. (OTCQB:
BIEI) is a research-based publicly traded company that intends
to discover and develop medical treatments for a wide range of
diseases in humans. Premier has obtained, via exclusive
license agreements, the technology behind three granted US Patents,
multiple pending provisional patents, and a PCT Europe National
Patent. Founded in 2010, Premier has partnered with the
Department of Defense with Center of Expertise at the William
Beaumont Army Medical Center and the University of Texas at El Paso
(UTEP). The company's R&D efforts are centered in El
Paso, TX, and their business offices are in Western Pennsylvania.
The Company is a fully-reporting issuer whose common stock trades
on the OTCQB marketplace maintained by OTC Markets Group, Inc.
under the ticker symbol "BIEI." For more information please
visit our website: http://www.premierbiomedical.com/.
Safe Harbor
Notice
Certain statements contained herein are
“forward-looking statements” (as defined in the Private Securities
Litigation Reform Act of 1995). Premier Biomedical, Inc.
cautions that statements, and assumptions made in this news release
constitute forward-looking statements and makes no guarantee of
future performance. Forward-looking statements are based on
estimates and opinions of management at the time statements are
made. These statements may address issues that involve
significant risks, uncertainties, estimates made by management.
Actual results could differ materially from current
projections or implied results. Premier Biomedical, Inc. undertakes
no obligation to revise these statements following the date of this
news release.
For more information
please contact:
William A.
Hartman
President and
CEO
Premier Biomedical
Inc.
(724)
633-7033
w.hartman@premierbiomedical.com
http://www.premierbiomedical.com/
Premier Biomedical (PK) (USOTC:BIEI)
Historical Stock Chart
From Sep 2024 to Oct 2024
Premier Biomedical (PK) (USOTC:BIEI)
Historical Stock Chart
From Oct 2023 to Oct 2024